coronavirus
group
envelop
nonseg
positivesens
rna
virus
larg
genom
size
rang
approxim
kb
infect
human
strain
usual
caus
mild
selflimit
respiratori
infect
common
nevertheless
past
year
three
beta
coronavirus
sarscov
merscov
year
caus
sever
human
diseas
pandem
associ
high
morbid
mortal
outbreak
sar
southern
china
novemb
juli
eventu
result
confirm
case
death
report
countri
mortal
rate
mer
first
identifi
saudi
arabia
caus
total
laboratoryconfirm
case
includ
associ
death
fatal
rate
nearli
end
januari
lack
effect
treatment
coronaviru
infect
pose
great
challeng
clinic
manag
highlight
urgent
need
new
drug
discoveri
wu
et
al
found
niclosamid
abl
inhibit
sarscov
replic
total
abolish
viral
antigen
synthesi
concentr
screen
small
market
drug
niclosamid
suppress
cytopath
effect
cpe
sarscov
concentr
low
inhibit
sarscov
replic
valu
less
vero
sarscov
proteas
play
import
role
replicas
polyprotein
process
serv
key
target
antisar
drug
seri
deriv
discov
potent
inhibitor
sarscov
proteas
interestingli
niclosamid
show
obviou
inhibitori
activ
sarscov
proteas
mechanist
may
exert
antisar
activ
via
mode
gassen
et
al
reveal
ligas
sphase
kinaseassoci
protein
execut
polyubiquitin
benclin
result
proteasom
degrad
inhibit
increas
level
enhanc
autophagi
effici
reduc
merscov
niclosamid
report
inhibit
merscov
replic
h
pi
concentr
enhanc
level
oligomer
increas
number
autolysosom
affect
autophag
flux
merscovinfect
sinc
niclosamid
multifunct
drug
exclud
possibl
exert
antim
activ
regul
target
besid
inhibit
flaviviru
genu
virus
famili
flavivirida
includ
zika
viru
zikv
dengu
viru
four
serotyp
denv
west
nile
viru
wnv
yellow
fever
viru
yfv
japanes
enceph
viru
jev
mani
virus
signific
human
pathogen
among
virus
zikv
mosquitoborn
flaviviru
transmit
primarili
aed
mosquito
zikv
infect
caus
infant
born
microcephali
trigger
neurolog
condit
adult
syndrom
neuropathi
outbreak
zikv
infect
record
sever
time
brazil
latest
one
world
health
organ
declar
zikv
global
public
health
emerg
xu
et
al
use
activ
primari
screen
assay
discov
niclosamid
potent
inhibitor
zikv
infect
display
valu
intracellular
zikv
rna
timeofaddit
studi
indic
niclosamid
inhibit
zikv
infect
postentri
stage
probabl
viral
rna
replic
step
research
team
also
identifi
niclosamid
potent
antizikv
inhibitor
independ
quantit
highthroughput
screen
qht
campaign
found
niclosamid
directli
inhibit
flaviviru
proteas
complex
essenti
flavivir
polyprotein
team
also
found
niclosamid
broadspectrum
inhibitor
flavivirus
includ
wnv
jev
yfv
potenc
similar
addit
fang
et
al
develop
cpebas
ht
assay
screen
pharmacolog
activ
compound
identifi
niclosamid
potent
jev
inhibitor
micromolar
timeofaddit
studi
show
niclosamid
inhibit
jev
stage
replic
hepat
c
viru
hcv
envelop
positivesens
singlestrand
rna
viru
famili
flavivirida
transmit
mainli
blood
infect
hcv
caus
acut
chronic
hepat
hepat
c
major
caus
liver
cancer
estim
million
peopl
chronic
hcv
infect
present
effect
vaccin
hepat
c
although
clinic
approv
therapeut
avail
niclosamid
report
show
promis
activ
hcv
replic
valu
like
inhibit
hcv
replic
via
modul
host
cell
process
similar
deriv
nitazoxanid
howev
chronic
hcv
infect
requir
longterm
sever
month
antivir
treatment
may
make
hosttarget
approach
less
attract
ebola
viru
ebov
envelop
negativesens
singlestrand
rna
viru
belong
genu
ebolaviru
famili
filovirida
ebov
introduc
human
wild
anim
spread
human
popul
persontoperson
transmiss
ebola
viru
diseas
evd
known
ebola
hemorrhag
fever
high
fatal
rate
rang
past
outbreak
systemat
screen
fdaapprov
drug
niclosamid
identifi
one
potent
ebov
inhibitor
valu
although
vivo
efficaci
yet
evalu
anim
human
rhinovirus
hrv
nonenvelop
positivesens
singlestrand
rna
virus
belong
genu
enteroviru
famili
picornavirida
differ
hrv
strain
classifi
three
speci
hrv
hrv
widespread
among
human
primari
caus
common
cold
pose
seriou
health
risk
patient
asthma
chronic
pulmonari
diseas
sever
bronchiol
infant
niclosamid
weak
lipophil
acid
report
inhibit
phdepend
hrv
infect
low
micromolar
valu
suppress
hrv
entri
block
acidif
endolysosom
compart
act
proton
chikungunya
viru
chikv
positivesens
singlestrand
rna
viru
belong
genu
alphaviru
famili
togavirida
chikv
caus
fever
joint
pain
transmit
infect
femal
mosquito
catalog
risk
pathogen
current
effect
antivir
therapi
approv
chikungunya
niclosamid
discov
potent
antichikv
inhibitor
low
micromolar
valu
affect
chikv
entri
via
block
lowphdepend
viru
fusion
also
inhibit
celltocel
transmiss
chikv
human
adenovirus
hadv
nonenvelop
doublestrand
dna
virus
icosahedr
capsid
hadv
compris
differ
serotyp
classifi
seven
speci
hadv
hadv
infect
caus
sever
often
lifethreaten
diseas
immunosuppress
patient
current
specif
antivir
therapi
avail
treat
infect
three
salicylanilid
anthelmint
drug
includ
niclosamid
screen
potent
antihadv
inhibitor
niclosamid
show
promis
antihadv
activ
valu
plaqu
assay
subsequ
mechanist
studi
indic
niclosamid
inhibit
transport
hadv
particl
endosom
nuclear
viru
ebv
also
known
human
herpesviru
toroidshap
protein
core
contain
linear
doublestrand
dna
genom
kb
size
member
gamma
subfamili
herp
virus
ebv
wide
spread
human
infect
human
first
decad
life
result
lymphoprolif
disord
known
infecti
mononucleosi
ebv
infect
also
found
associ
develop
sever
type
cancer
burkitt
lymphoma
hodgkin
lymphoma
nasopharyng
huang
et
al
demonstr
niclosamid
inhibit
ebv
lytic
replic
lymphoma
cell
epitheli
cell
caus
irrevers
cell
cycl
arrest
lytic
ebvinfect
cell
via
disrupt
mtor
activ
offer
potenti
treat
acut
ebvassoci
infecti
niclosamid
tradit
use
treat
tapeworm
infect
mani
year
inexpens
well
toler
vivo
extrem
high
acut
oral
valu
mgkg
rat
niclosamid
ethanolamin
salt
human
medicin
singl
oral
dose
g
niclosamid
recommend
children
year
children
year
children
older
year
adult
respect
treat
infect
taenia
solium
saginata
diphyllobothrium
human
infect
rat
tapeworm
hymenolepi
diminuta
elimin
daili
dose
g
niclosamid
treatment
hymenolepi
nana
infect
requir
one
sever
day
cours
niclosamid
treatment
one
day
cours
regimen
adult
g
niclosamid
day
follow
g
daili
treat
human
volunt
singl
oral
dose
mg
niclosamid
maximum
serum
concentr
niclosamid
equival
wide
concentr
rang
caus
intraindividu
absorpt
differ
niclosamid
partial
absorb
intestin
tract
absorb
part
rapidli
elimin
kidney
cumul
toxic
effect
seri
drug
repurpos
screen
campaign
niclosamid
found
effect
varieti
human
condit
cancer
viral
infect
current
four
ongo
human
clinic
trial
niclosamid
ulcer
coliti
prostat
carcinoma
colorect
cancer
clinicaltrailsgov
clinic
trial
note
niclosamid
sever
weak
unneglect
cytotox
limit
aqueou
solubl
well
rel
low
absorpt
oral
bioavail
f
may
hamper
extens
clinic
develop
antivir
group
made
substanti
effort
medicin
chemistri
base
niclosamid
lead
compound
discov
seri
oalkylaminoteth
deriv
potent
oral
bioavail
anticanc
agent
improv
aqueou
diversifi
salicylamid
deriv
potent
antihadv
inhibitor
increas
potenc
submicromolar
significantli
decreas
cytotox
like
target
differ
step
hadv
life
ester
deriv
prodrug
niclosamid
also
report
increas
system
drug
exposur
extend
durat
develop
nanobas
formul
anoth
use
strategi
improv
pharmacolog
pharmacokinet
properti
niclosamid
maxim
therapeut
potenti
clinic
outbreak
declar
public
health
emerg
intern
concern
develop
effect
therapi
fastspread
fatal
urgent
need
proteas
key
enzym
respons
proteolyt
process
indispens
viral
replic
infect
recent
highresolut
crystal
structur
proteas
solv
zihe
rao
haitao
yang
pdb
id
figur
may
significantli
facilit
discoveri
potent
smallmolecul
inhibitor
target
proteas
via
highthroughput
virtual
screen
compound
librari
exist
drug
librari
drug
repurpos
addit
wrapp
et
al
determin
cryoem
structur
spike
glycoprotein
trimer
prefus
conform
also
facilit
vaccin
develop
discoveri
antivir
therapeut
although
crystal
structur
may
provid
new
insight
help
inform
futur
drug
discoveri
extens
effort
need
identifi
effect
bind
pocket
small
molecul
valid
drug
target
report
exist
drug
drug
candid
remdesivir
rnadepend
rna
polymeras
rdrp
inhibitor
lopinavirritonavir
proteas
inhibitor
ebola
hiv
may
repurpos
fasttrack
human
clinic
trial
effect
therapi
combat
deadli
save
hundr
patient
recent
screen
exist
antivir
drug
three
broad
antivir
agent
nitazoxanid
remdesivir
chloroquin
found
inhibit
low
micromolar
concentr
vero
cell
valu
nitazoxanid
prodrug
tizoxanid
share
consider
structur
similar
niclosamid
salicylamid
notabl
niclosamid
display
promis
inhibitori
activ
sarscov
replic
valu
less
vero
cell
inhibit
merscov
replic
h
pi
concentr
vero
belong
genu
betacoronaviru
sarscov
merscov
share
sequenc
identifi
find
togeth
broad
antivir
properti
indic
niclosamid
inexpens
welltoler
old
drug
may
repurpos
therapeut
potenti
applic
combat
envis
activ
valid
anim
model
human
clinic
trial
niclosamid
optim
analogu
may
develop
effect
antivir
therapeut
potenti
benefit
numer
infect
patient
outbreak
